Results 51 to 60 of about 13,218 (206)

Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials. [PDF]

PLoS ONE, 2013
The development of tipranavir and darunavir, second generation non-peptidic HIV protease inhibitors, with marked improved resistance profiles, has opened a new perspective on the treatment of antiretroviral therapy (ART) experienced HIV patients with ...
Asres Berhan, Yifru Berhan
doaj   +1 more source

Validation of an UHPLC–MS/MS Assay for the Quantification of Isoniazid and Four Major Metabolites in Human Plasma

Biomedical Chromatography, Volume 40, Issue 9, September 2026.
ABSTRACT Isoniazid (INH) is a key component of tuberculosis treatment regimens but is also associated with hepatotoxicity. This toxicity is mediated in part by its metabolites, but some degrade rapidly in plasma. A rapid freeze/thaw process with a methanol protein precipitation extraction was developed to slow the rapid degradation of acetylisoniazid ...
David Nerguizian, Brandon Klein, Farah Abdelmawla, Joe Gomez, Peter L. Anderson, Lane Bushman, Kristina M. Brooks   +6 more
wiley   +1 more source

Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort

Frontiers in Cellular and Infection Microbiology
BackgroundDrug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ritonavir have been repurposed as treatments for COVID-19 ...
Dóra Paróczai, Dóra Paróczai, András Bikov, András Bikov, Andreea Blidaru, Emanuel Bobu, Ana Lascu, Ana Lascu, Cristian Ion Mot, Cristian Ion Mot, Stefan Mihaicuta, Stefan Mihaicuta, Stefan Frent, Stefan Frent   +13 more
doaj   +1 more source

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.

PLoS ONE, 2022
BackgroundCoronavirus Disease 2019 (COVID-19) is an evolving pandemic that urged the need to investigate various antiviral therapies. This study was conducted to compare efficacy and safety outcomes of darunavir-cobicistat versus lopinavir-ritonavir in ...
Eman Zeyad I Elmekaty, Rim Alibrahim, Rania Hassanin, Sitelbanat Eltaib, Ahmed Elsayed, Fatima Rustom, Mohamed Izham Mohamed Ibrahim, Mohammed Abu Khattab, Hussam Al Soub, Muna Al Maslamani, Abdullatif Al-Khal   +10 more
doaj   +1 more source

Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance

mBio, 2018
Darunavir (DRV) has bimodal activity against HIV-1 protease, enzymatic inhibition and protease dimerization inhibition, and has an extremely high genetic barrier against development of drug resistance. We previously generated a highly DRV-resistant HIV-1
Manabu Aoki, Debananda Das, Hironori Hayashi, Hiromi Aoki-Ogata, Yuki Takamatsu, Arun K. Ghosh, Hiroaki Mitsuya   +6 more
doaj   +1 more source

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV [PDF]

, 2021
OBJECTIVE: To evaluate darunavir and cobicistat pharmacokinetics during pregnancy compared to postpartum and in infant washout samples after delivery. DESIGN: Nonrandomized, open-label, parallel-group, multi-center phase-IV prospective study of darunavir
RUNGRUENGTHANAKIT, Kittipong, Mark Mirochnick, Kayla Denson, Mary E. Paul, Sandra Burchett, MOMPER, Jeremiah D., Best, Brookie M, Alice Stek, SHAPIRO, David E., David E. Shapiro, BEST, Brookie M., Jeremiah D. Momper, BURCHETT, Sandra, YANG, Derek, Yang, Derek Z, CAPPARELLI, Edmund V., WANG, Jiajia, Kathleen George, STEK, Alice, Capparelli, Edmund V, CHAKHTOURA, Nahida, DENSON, Kayla, Momper, Jeremiah D, Shapiro, David E, FEBO, Irma L., PAUL, Mary E., SMITH, Elizabeth, Jiajia Wang, Kittipong Rungruengthanakit, Nahida Chakhtoura, Gwendolyn B. Scott, Irma L. Febo, Brookie M. Best, Elizabeth Smith, Febo, Irma L, Derek Z. Yang, GEORGE, Kathleen, Edmund V. Capparelli, SCOTT, Gwendolyn B., Scott, Gwendolyn B, Paul, Mary E, MIROCHNICK, Mark   +41 more
core   +1 more source

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil

Brazilian Journal of Infectious Diseases, 2013
Objectives: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil.
José Ernesto Vidal, Alice Tung Wan Song, Maria Laura Matos, Daniel Bartmann, Guilherme dos Anjos, Érique José Peixoto de Miranda, Ângela Carvalho Freitas, Mirian de Freitas Dalben, Claudinei Santana, Aluísio Cotrim Segurado, Cláudia Cortese Barreto, Adrián Vladimir Hernández   +11 more
doaj   +1 more source

96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation

HIV Research & Clinical Practice, 2020
Antiretroviral therapies have been tested with the goal of maintaining virological suppression with a particular attention in limiting drug-related toxicity.
Valentina Di Cristo, Fulvio Adorni, Renato Maserati, Marco Annovazzi Lodi, Giuseppe Bruno, Paolo Maggi, Anna Volpe, Paola Vitiello, Clara Abeli, Stefano Bonora, Micol Ferrara, Maria Vittoria Cossu, Maria Letizia Oreni, Elisa Colella, Stefano Rusconi   +14 more
doaj   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, Volume 27, Issue 9, Page 1399-1420, September 2026.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

Herb-Drug Interaction between Echinacea purpurea and Darunavir-Ritonavir in HIV-Infected Patients

, 2011
The aim of this open-label, fixed-sequence study was to investigate the potential of Echinacea purpurea , a commonly used botanical supplement, to interact with the boosted protease inhibitor darunavir-ritonavir.
Eugenia Negredo, Cristina Miranda, Marta Valle, José Moltó, Bonaventura Clotet, Samandhy Cedeño, Manuel José Barbanoj   +6 more
core   +1 more source